JOURNAL DESCRIPTION
The Medical Radiology and Radiation Safety journal ISSN 1024-6177 was founded in January 1956 (before December 30, 1993 it was entitled Medical Radiology, ISSN 0025-8334). In 2018, the journal received Online ISSN: 2618-9615 and was registered as an electronic online publication in Roskomnadzor on March 29, 2018. It publishes original research articles which cover questions of radiobiology, radiation medicine, radiation safety, radiation therapy, nuclear medicine and scientific reviews. In general the journal has more than 30 headings and it is of interest for specialists working in thefields of medicine¸ radiation biology, epidemiology, medical physics and technology. Since July 01, 2008 the journal has been published by State Research Center - Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency. The founder from 1956 to the present time is the Ministry of Health of the Russian Federation, and from 2008 to the present time is the Federal Medical Biological Agency.
Members of the editorial board are scientists specializing in the field of radiation biology and medicine, radiation protection, radiation epidemiology, radiation oncology, radiation diagnostics and therapy, nuclear medicine and medical physics. The editorial board consists of academicians (members of the Russian Academy of Science (RAS)), the full member of Academy of Medical Sciences of the Republic of Armenia, corresponding members of the RAS, Doctors of Medicine, professor, candidates and doctors of biological, physical mathematics and engineering sciences. The editorial board is constantly replenished by experts who work in the CIS and foreign countries.
Six issues of the journal are published per year, the volume is 13.5 conventional printed sheets, 88 printer’s sheets, 1.000 copies. The journal has an identical full-text electronic version, which, simultaneously with the printed version and color drawings, is posted on the sites of the Scientific Electronic Library (SEL) and the journal's website. The journal is distributed through the Rospechat Agency under the contract № 7407 of June 16, 2006, through individual buyers and commercial structures. The publication of articles is free.
The journal is included in the List of Russian Reviewed Scientific Journals of the Higher Attestation Commission. Since 2008 the journal has been available on the Internet and indexed in the RISC database which is placed on Web of Science. Since February 2nd, 2018, the journal "Medical Radiology and Radiation Safety" has been indexed in the SCOPUS abstract and citation database.
Brief electronic versions of the Journal have been publicly available since 2005 on the website of the Medical Radiology and Radiation Safety Journal: http://www.medradiol.ru. Since 2011, all issues of the journal as a whole are publicly available, and since 2016 - full-text versions of scientific articles. Since 2005, subscribers can purchase full versions of other articles of any issue only through the National Electronic Library. The editor of the Medical Radiology and Radiation Safety Journal in accordance with the National Electronic Library agreement has been providing the Library with all its production since 2005 until now.
The main working language of the journal is Russian, an additional language is English, which is used to write titles of articles, information about authors, annotations, key words, a list of literature.
Since 2017 the journal Medical Radiology and Radiation Safety has switched to digital identification of publications, assigning to each article the identifier of the digital object (DOI), which greatly accelerated the search for the location of the article on the Internet. In future it is planned to publish the English-language version of the journal Medical Radiology and Radiation Safety for its development. In order to obtain information about the publication activity of the journal in March 2015, a counter of readers' references to the materials posted on the site from 2005 to the present which is placed on the journal's website. During 2015 - 2016 years on average there were no more than 100-170 handlings per day. Publication of a number of articles, as well as electronic versions of profile monographs and collections in the public domain, dramatically increased the number of handlings to the journal's website to 500 - 800 per day, and the total number of visits to the site at the end of 2017 was more than 230.000.
The two-year impact factor of RISC, according to data for 2017, was 0.439, taking into account citation from all sources - 0.570, and the five-year impact factor of RISC - 0.352.
Medical Radiology and Radiation Safety. 2026. Vol. 71. № 4
DOI:10.33266/1024-6177-2026-71-4-21-31
E.E. Karmanova1, S.B. Parfenyuk1, O.V. Glushkova1, S.V. Gudkov2, V.I. Novoselov1, M.G. Sharapov1
THE ROLE OF PEROXIREDOXINS IN THE RADIORESISTANCE OF CANCER CELLS
1 Institute of Cell Biophysics, Moscow Region, Pushchino, Russia
2 A.M. Prokhorov General Physics Institute, Moscow, Russia
Contact person: M.G. Sharapov, e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
ABSTRACT
Peroxiredoxins (Prdxs) are a family of thiol-dependent peroxidases involved in controlling intracellular ROS levels, redox signaling, protein folding, and the regulation of numerous signaling pathways. In cancer cells, Prdxs help maintain redox balance and support oncogenic processes, promoting proliferation, survival, and adaptation to oxidative stress. During radiotherapy, Prdxs act as key mediators of radioresistance. Their contribution to radioresistance stems from their involvement in the reduction of a broad range of hydroperoxides, the repair of DNA damage, metabolic reprogramming, maintenance of phenotypic plasticity, remodeling of the tumor microenvironment, and the regulation of various forms of cell death (apoptosis, ferroptosis, necroptosis).
This review summarizes current knowledge on the structural and functional characteristics of different Prdx isoforms and their regulation, as well as the mechanisms through which they participate in the cellular response to ionizing radiation. Promising strategies for overcoming radioresistance are discussed, including the use of Prdx inhibitors, their combination with targeted therapies, and approaches aimed at redox modulation and suppression of stress-adaptive mechanisms in cancer cells.
Keywords: peroxiredoxins, reactive oxygen species, cancer, radiotherapy, radioresistance, cell death
For citation: Karmanova EE, Parfenyuk SB, Glushkova OV, Gudkov SV, Novoselov VI, Sharapov MG. The Role of Peroxiredoxins in the Radioresistance of Cancer Cells. Medical Radiology and Radiation Safety. 2026;71(4):21–31. DOI:10.33266/1024-6177-2026-71-4-21-31
References
1. Porrazzo A., Cassandri M., D’Alessandro A., Morciano P., Rota R., Marampon F., Cenci G. DNA Repair in Tumor Radioresistance: Insights from Fruit Flies Genetics. Cell Oncol (Dordr). 2024;47;3:717–32. Doi: 10.1007/s13402-023-00906-6. PMID: 38095764.
2. Zhou T., Zhang L.Y., He J.Z., Miao Z.M., Li Y.Y., Zhang Y.M., Liu Z.W., Zhang S.Z., Chen Y., Zhou G.C., Liu Y.Q. Review: Mechanisms and Perspective Treatment of Radioresistance in Non-Small Cell Lung Cancer. Front Immunol. 2023 Feb;14:1133899. Doi: 10.3389/fimmu.2023.1133899. PMID: 36865554.
3. Hao J., Song Z., Su J., Li L., Zou L., Zou K. The PRX-1/TLR4 Axis Promotes Hypoxia-Induced Radiotherapy Resistance in Non-Small Cell Lung Cancer by Targeting the NF-κB/p65 Pathway. Cell Signal. 2023;110:110806. Doi: 10.1016/j.cellsig.2023.110806. PMID: 37468052.
4. Sharapov M.G., Karmanova E.E., Gudkov S.V. Mechanisms of Cancer Cell Radioresistance: Modern Trends and Research Prospects. Biophysics. 2024;69:1064–88. Doi: 10.1134/S0006350924701161.
5. Guan X., Ruan Y., Che X., Feng W. Dual Role of PRDX1 in Redox-Regulation and Tumorigenesis: Past and Future. Free Radic Biol Med. 2024;210:120–9. Doi: 10.1016/j.freeradbiomed.2023.11.009. PMID: 37977211.
6. Forshaw T.E., Holmila R., Nelson K.J., Lewis J.E., Kemp M.L., Tsang A.W., Poole L.B., Lowther W.T., Furdui C.M. Peroxiredoxins in Cancer and Response to Radiation Therapies. Antioxidants (Basel). 2019;8;1:11. Doi: 10.3390/antiox8010011. PMID: 30609657.
7. Egetemaier S.M., Chauvistré H., Váraljai R., Hua Y., Lueong S.S., Makhzami S., Srinivas N., Forster J., Ullrich V., Stupia S., Schroeder V., Scharfenberg S., Hoewner A., Shannan B., Siveke J.S., Baietti M.F., Leucci E., Marine J.C., Paschen A., Scheffler B., Engel D.R., Becker L.M., Thedieck K., Nensa F., Koester J., Grünwald B.T., Poepsel S., Ninck S., Kaschani F., Schadendorf D., Becker J.C., Tasdogan A., Rambow F., Roesch A. Redirecting Resistance Evolution in BRAFV600 Melanoma by Inhibition of the Peroxiredoxin-Thioredoxin System. Health Med Week. 2025;4:3417. Doi: 10.1101/2025.03.10.641595.
8. Kazama H., Wang Y.H., Tanaka J. Tyrosine Kinase Inhibitors Modulate the Expression of Peroxiredoxins 1 and 2 in Chronic Myeloid Leukemia Cells. Leuk Res Rep. 2025;23:100508. Doi: 10.1016/j.lrr.2025.100508. PMID: 40206283.
9. Qausain S., Basheeruddin M. Unraveling the Peroxidase Activity in Peroxiredoxins: a Comprehensive Review of Mechanisms, Functions, and Biological Significance. Cureus. 2024;16;8:e66117. Doi: 10.7759/cureus.66117. PMID: 39229430.
10. Sharapov M.G., Goncharov R.G., Parfenyuk S.B., Glushkova O.V. Effect of Peroxiredoxin 6 on p53 Transcription Factor Level. Biochemistry (Mosc). 2022;87;8:839-49. Doi: 10.1134/S0006297922080156. PMID: 36171649.
11. Ben Diouf O., Gilbert A., Bernay B., Syljuasen R.G,. Tudor M., Temelie M., Savu D.I., Soumboundou M., Sall C., Chevalier F. Phospho-Proteomics Analysis of Early Response to X-Ray Irradiation Reveals Molecular Mechanism Potentially Related to U251 Cell Radioresistance. Proteomes. 2024;13;1:1. Doi: 10.3390/proteomes13010001. PMID: 39846632.
12. Shrestha J., Limbu K.R., Chhetri R.B., Paudel K.R., Hansbro P.M., Oh Y.S., Baek D.J., Ki S.H., Park E.Y. Antioxidant Genes in Cancer and Metabolic Diseases: Focusing on Nrf2, Sestrin, and heme Oxygenase 1. Int J Biol Sci. 2024;20;12:4888-907. Doi: 10.7150/ijbs.98846. PMID: 39309448.
13. Peng L., Xiong Y., Wang R., Xiang L., Zhou H., Fu Z. The Critical Role of Peroxiredoxin-2 in Colon Cancer Stem Cells. Aging (Albany NY). 2021;13;8:11170-87. Doi: 10.18632/aging.202784. PMID: 33819194.
14. Moretton A., Kourtis S., Gañez Zapater A., Calabrò C., Espinar Calvo M.L., Fontaine F., Darai E., Abad Cortel E., Block S., Pascual-Reguant L., Pardo-Lorente N., Ghose R., Vander Heiden M.G., Janic A., Müller A.C., Loizou J.I., Sdelci S. A Metabolic Map of the DNA Damage Response Identifies PRDX1 in the Control of Nuclear ROS Scavenging and Aspartate Availability. Mol Syst Biol. 2023;19;7:e11267. Doi: 10.15252/msb.202211267. PMID: 37259925.
15. Abdullah N.A., Md Hashim N.F., Muhamad Zakuan N., Chua J.X. Thioredoxin System in Colorectal Cancer: its Role in Carcinogenesis, Disease Progression, and Response to Treatment. Life Sci. 2024;348:122711. Doi: 10.1016/j.lfs.2024.122711. PMID: 38734065.
16. Gu X., Mu C., Zheng R., Zhang Z., Zhang Q., Liang T. The Cancer Antioxidant Regulation System in Therapeutic Resistance. Antioxidants (Basel). 2024;13;7:778. Doi: 10.3390/antiox13070778. PMID: 39061847.
17. Dai X., Xi M., Li J. Cancer Metastasis: Molecular Mechanisms and Therapeutic Interventions. Mol Biomed. 2025;6;1:20. Doi: 10.1186/s43556-025-00261-y. PMID: 40192949.
18. Zhang K., Nie J., Wu Y., Lu Z., Qiu Z., Li Z., Zhong Y., Cheng H. Epidermal Growth Factor Receptor Targeted Photodynamic Degrader to Activate Breast Cancer Immunity by Intensifying Immunogenic Cell Death and Downregulating PD-L1. Chem Eng J. 2025;507:160811. Doi: 10.1016/j.cej.2025.160811.
19. Nguyen V.K., Tsai S.W., Cho I.C., Chao T.C., Hsiao I.T., Huang H.C., Liaw J.W. Gold Nanoparticle-Enhanced Production of Reactive Oxygen Species for Radiotherapy and Phototherapy. Nanomaterials (Basel). 2025;15;4:317. Doi: 10.3390/nano15040317. PMID: 39997879.
20. Liu Y., Wang P., Hu W., Chen D. New Insights into the Roles of Peroxiredoxins in Cancer. Biomed Pharmacother. 2023;164:114896. Doi: 10.1016/j.biopha.2023.114896. PMID: 37210897.
21. Zhao K., Zhao T., Yang R., Liu J., Hu M. Peroxiredoxin 2 as a Potential Prognostic Biomarker Associated with Angiogenesis in Cervical Squamous Cell Cancer. Oncol Lett. 2024;28;1:328. Doi: 10.3892/ol.2024.14461. PMID: 38807674.
22. Yoon Y.J., Lee Y.J., Choi J., Chi S.W., Lee S., Park K.C., Kwon B.M., Han D.C. 2′-Hydroxycinnamaldehyde Induces ROS-mediated Apoptosis in Cancer Cells by Targeting PRX1 and PRX2. Results Chem. 2025;13:101931. Doi: 10.1016/j.rechem.2024.101931.
23. Pace P.E., Fu L., Hampton M.B., Winterbourn C.C. Effect of Peroxiredoxin 1 or Peroxiredoxin 2 Knockout on the Thiol Proteome of Jurkat Cells. Free Radic Biol Med. 2024 Nov 20;225:595–604. Doi: 10.1016/j.freeradbiomed.2024.10.293. PMID: 39427748.
24. Gibson V., Rogel J., Dzialo J., Messier T., Habibovic A., Poile C., Nakas A., Kutywayo K., Bzura A., Naumov G., Fennell D., Cunniff B. Peroxiredoxin 3 is a Key Regulator of Mesothelioma Progression and a Target for Therapeutic Intervention [Abstract]. Proceedings of the American Association for Cancer Research Annual Meeting 2025. Part 1 (Regular Abstracts). Chicago, 2025 Apr 25-30; Philadelphia, AACR. Cancer Res 2025;85;8 Suppl 1: Abstract nr 4259.
25. Liao J., Zhang Y., Yang J., Chen L., Zhang J., Chen X. Peroxiredoxin 6 in Stress Orchestration and Disease Interplay. Antioxidants (Basel). 2025;14;4:379. Doi: 10.3390/antiox14040379. PMID: 40298631.
26. Lagal D.J., Ortiz-Alcántara Á., Pedrajas J.R., McDonagh B., Bárcena J.A., Requejo-Aguilar R., Padilla C.A. Loss of Peroxiredoxin 6 Alters Lipid Composition and Distribution Resulting in Increased Sensitivity to Ferroptosis. Biochem J. 2024;481;24:1997-2015. Doi: 10.1042/BCJ20240445. PMID: 39601357.
27. Lagal D.J., Montes-Osuna A.M., Ortiz-Olivencia A., Arribas-Parejas C., Ortiz-Alcántara Á., Pescuezo-Castillo C., Bárcena J.A., Padilla C.A., Requejo-Aguilar R. Tumoral Malignancy Decreases Coupled with higher ROS and Lipid Peroxidation in HCT116 Colon Cancer Cells Upon Loss of PRDX6. Antioxidants (Basel). 2024;13;7:881. Doi: 10.3390/antiox13070881. PMID: 39061949.
28. Cao X., Chen X.M., Xiao W.Z., Li B., Zhang B., Wu Q., Xue Q. ROS-Mediated Hypomethylation of PRDX5 Promotes STAT3 Binding and Activates the Nrf2 Signaling Pathway in NSCLC. Int J Mol Med. 2021;47;2:573–82. Doi: 10.3892/ijmm.2020.4819. PMID: 33416106.
29. Ou Y., Shen C., Chen Z., Liu T., Peng Y., Zong D., Ouyang R. TDP43/HDAC6/Prdx1 Signaling Pathway Participated in the Cognitive Impairment of Obstructive Sleep Apnea Via Regulating Inflammation and Oxidative Stress. Int Immunopharmacol. 2024;127:111350. Doi: 10.1016/j.intimp.2023.111350. PMID: 38104368.
30. Labbé M., Chang M., Saintpierre B., Letourneur F., de Beaurepaire L., Véziers J., Deshayes S., Cotinat M., Fonteneau J.F., Blanquart C., Potiron V., Supiot S., Fradin D. Loss of miR-200c-3p Promotes Resistance to Radiation Therapy Via the DNA Repair Pathway in Prostate Cancer. Cell Death Dis. 2024;15;10:751. Doi: 10.1038/s41419-024-07133-3. PMID: 39414799.
31. Jiang Y., Cao W., Wu K., Qin X., Wang X., Li Y., Yu B., Zhang Z., Wang X., Yan M., Xu Q., Zhang J., Chen W. LncRNA LINC00460 Promotes EMT in Head and Neck Squamous Cell Carcinoma by Facilitating Peroxiredoxin-1 Into the Nucleus. J Exp Clin Cancer Res. 2019;38;1:365. Doi: 10.1186/s13046-019-1364-z. PMID: 31429766.
32. Zhang R., Chen D. O-GlcNAcylation of PRDX1 and Radiation Resistance in Non-Small Cell Lung Cancer via Suppressing TRIM21 Mediated Ubiquitination. Int J Radiat Oncol Biol Phys. 2024;120;2:S30–S31. Doi: 10.1016/j.ijrobp.2024.07.041.
33. Sun H.N., Ma D.Y., Guo X.Y., Hao Y.Y., Jin M.H., Han Y.H., Jin X., Kwon T. Peroxiredoxin I and II as Novel Therapeutic Molecular Targets in Cervical Cancer Treatment through Regulation of Endoplasmic Reticulum Stress Induced by Bleomycin. Cell Death Discov. 2024;10;1:267. Doi: 10.1038/s41420-024-02039-7. PMID: 38821929.
34. Yang W., Zhu Z., Zhou C., Chen J., Ou J., Tong H., Iyaswamy A., Chen P., Wei X., Yang C., Xiao W., Wang J., Zhang W. The Rheumatoid Arthritis drug Auranofin Targets Peroxiredoxin 1 and Peroxiredoxin 2 to Trigger ROS-Endoplasmic Reticulum Stress Axis-Mediated Cell Death and Cytoprotective Autophagy. Free Radic Biol Med. 2025;233:1–12. Doi: 10.1016/j.freeradbiomed.2025.03.016. PMID: 40089079.
35. Zhou Y., Wang M., Qian Y., Yu D., Zhang J., Fu M., Zhang X., Qin R., Ji R., Zhang X., Gu J. PRDX2 Promotes Gastric Cancer Progression by Forming a Feedback Loop with PKM2/STAT3 Axis. Cell Signal. 2025;127:111586. Doi: 10.1016/j.cellsig.2024.111586. PMID: 39761843.
36. Feng K., Li X., Bai Y., Zhang D., Tian L. Mechanisms of Cancer Cell Death Induction by Triptolide: A Comprehensive Overview. Heliyon. 2024;10;2:e24335. Doi: 10.1016/j.heliyon.2024.e24335. PMID: 38293343.
37. Skoko J.J., Cao J., Gaboriau D., Attar M., Asan A., Hong L., Paulsen C.E., Ma H., Liu Y., Wu H., Harkness T., Furdui C.M., Manevich Y., Morrison C.G., Brown E.T., Normolle D., Spies M., Spies M.A., Carroll K., Neumann C.A. Redox Regulation of RAD51 Cys319 and Homologous Recombination by Peroxiredoxin 1. Redox Biol. 2022;56:102443. Doi: 10.1016/j.redox.2022.102443. PMID: 36058112.
38. Liao H., Yang S., Liang Z., Xiao L., Xie S., Lin P., Xia F., Fang C., Chen Q., Ling D., Li F. A Cancer Cell Selective Replication Stress Nano Amplifier Promotes Replication Fork Catastrophe to Overcome Radioresistance. ACS Nano. 2023;17;18:18548–61. Doi: 10.1021/acsnano.3c06774. PMID: 37706454.
39. An D., Zhai D., Wan C., Yang K. The Role of Lipid Metabolism in Cancer Radioresistance. Clin Transl Oncol. 2023;25;8:2332–49. Doi: 10.1007/s12094-023-03134-4. PMID: 37079212.
40. Li J., Li W., Li L., Wang W., Zhang M., Tang X. Induction of Peroxiredoxin 1 by Hypoxia Promotes Cellular Autophagy and Cell Proliferation in Oral Leukoplakia via HIF-1α/BNIP3 Pathway. J Mol Histol. 2024;55;4:403–13. Doi: 10.1007/s10735-024-10197-2. PMID: 38758520.
41. Jezierska-Drutel A., Attaran S., Hopkins B.L., Skoko J.J., Rosenzweig S.A., Neumann C.A. The peroxidase PRDX1 Inhibits the Activated Phenotype in Mammary Fibroblasts through Regulating c-Jun N-Terminal Kinases. BMC Cancer. 2019;19;1:812. Doi: 10.1186/s12885-019-6031-4. PMID: 31419957.
42. Wang L.Y., Liu X.J., Li Q.Q., Zhu Y., Ren H.L., Song J.N., Zeng J., Mei J., Tian H.X., Rong D.C., Zhang S.H. The Romantic History of Signaling Pathway Discovery in Cell Death: an Updated Review. Mol Cell Biochem. 2024;479;9:2255–72. Doi: 10.1007/s11010-023-04873-2. PMID: 37851176.
43. Hill R.M., Fok M., Grundy G., Parsons J.L., Rocha S. The Role of Autophagy in Hypoxia-Induced Radioresistance. Radiother Oncol. 2023;189:109951. Doi: 10.1016/j.radonc.2023.109951. PMID: 37838322.
44. Sun H.H., Li Y.L., Jiang H., Yin X.H., Jin X.L. PRDX1 Influences the Occurrence and Progression of Liver Cancer by Inhibiting Mitochondrial Apoptosis Pathway. Cell J. 2022;24;11:657–4. Doi: 10.22074/cellj.2022.8159. PMID: 36377215.
45. Liu W., Xu L., Wang X., Zhang D., Sun G., Wang M., Wang M., Han Y., Chai R., Wang H. PRDX1 Activates Autophagy via the PTEN-AKT Signaling Pathway to Protect against Cisplatin-Induced spiral Ganglion Neuron Damage. Autophagy. 2021 Dec;17;12:4159–81. Doi: 10.1080/15548627.2021.1905466. PMID: 33749526.
46. Li J., Sun Y., Zhao X., Ma Y., Xie Y., Liu S., Hui B., Shi X., Sun X., Zhang X. Radiation Induces IRAK1 Expression to Promote Radioresistance by Suppressing Autophagic Cell Death Via Decreasing the Ubiquitination of PRDX1 in Glioma Cells. Cell Death Dis. 2023;14;4:259. Doi: 10.1038/s41419-023-05732-0. PMID: 37031183.
47. Yu G., Song X., Chen Q., Zhou Y. Silencing of Peroxiredoxin III Inhibits Formaldehyde-Induced Oxidative Damage of Bone Marrow Cells in BALB/c Mice. Environ Toxicol. 2023;38;12:2836–44. Doi: 10.1002/tox.23915. PMID: 37584494.
48. López-Grueso M.J., Lagal D.J., García-Jiménez Á.F., Tarradas R.M., Carmona-Hidalgo B., Peinado J., Requejo-Aguilar R., Bárcena J.A., Padilla C.A. Knockout of PRDX6 Induces Mitochondrial Dysfunction and Cell Cycle Arrest at G2/M in HepG2 Hepatocarcinoma Cells. Redox Biol. 2020;37:101737. Doi: 10.1016/j.redox.2020.101737. PMID: 33035814.
49. Chen X., Zhang L., He Y., Huang S., Chen S., Zhao W., Yu D. Regulation of m6A Modification on Ferroptosis and its Potential Significance in Radiosensitization. Cell Death Discov. 2023;9;1:343. Doi: 10.1038/s41420-023-01645-1. PMID: 37714846.
50. Torres-Velarde J.M., Allen K.N., Salvador-Pascual A., Leija R.G., Luong D., Moreno-Santillán D.D., Ensminger D.C., Vázquez-Medina J.P. Peroxiredoxin 6 Suppresses Ferroptosis in Lung Endothelial Cells. Free Radic Biol Med. 2024;218:82–93. Doi: 10.1016/j.freeradbiomed.2024.04.208. PMID: 38579937.
51. Janssens S., Rennen S., Agostinis P. Decoding Immunogenic Cell Death from a Dendritic Cell Perspective. Immunol Rev. 2024 Jan;321;1:350-370. Doi: 10.1111/imr.13301. PMID: 38093416.
52. Ding Y., Ye B., Sun Z., Mao Z., Wang W. Reactive Oxygen Species-Mediated Pyroptosis with the Help of Nanotechnology: Prospects for Cancer Therapy. Adv NanoBiomed Res. 2023;3;1:2200077. Doi: 10.1002/anbr.202200077.
53. Rius-Pérez S. P53 at the Crossroad between Mitochondrial Reactive Oxygen Species and Necroptosis. Free Radic Biol Med. 2023;207:183–93. Doi: 10.1016/j.freeradbiomed.2023.07.022. PMID: 37481144.
54. Li Y., Zhu Y., Shang F.F., Xu L., Jiang D., Sun B., Zhang L., Luo C., Zhang A., Zhang H., Ding C. Discovery of Urea Derivatives of Celastrol as Selective Peroxiredoxin 1 Inhibitors against Colorectal Cancer Cells. J Med Chem. 2024;67;9:7176–96. Doi: 10.1021/acs.jmedchem.4c00023. PMID: 38679872.
55. Liu X., Zheng T., Bao Y., Li P., Zhao T., Liu Y., Wang H., Sun C. Genistein Implications in Radiotherapy: Kill Two Birds with One Stone. Molecules. 2025;30;1:188. Doi: 10.3390/molecules30010188. PMID: 39795243.
56. Farsiabi R., Khodadadi I., Karimi J., Shafiee Gh. The Effects of Genistein on Peroxiredoxin-4 and Oxidative Stress in Lung Cancer Cell Line A549. J Babol Univ Med Sci. 2024;26:e53. Doi: 10.22088/jbums.26.1.53.
57. Sun X., Wan X., Chen L., Cui Y., Chen X., Zhang J., Jiang X. Mitomycin Induced the Senescence of Alveolar Epithelial Cells by Targeting Peroxiredoxin I. Biochem Pharmacol. 2025;236:116890. Doi: 10.1016/j.bcp.2025.116890. PMID: 40139326.
58. Zhang H.N., Xiao W.Q., Lee D.H., Li N., Feng Y.Y., Su T., Gu H.Y., Yoon I., Jung H., Lee K.H., Cho H.J., Han Y.H., Sun H.N., Kwon T. Cisplatin Induces Kidney Cell Death via ROS-dependent MAPK Signaling Pathways by Targeting Peroxiredoxin I and II in African Green Monkey (Chlorocebus Aethiops Sabaeus) Kidney Cells. In Vivo. 2024;38;2:630–9. Doi: 10.21873/invivo.13482. PMID: 38418129; PMCID: PMC10905483.
59. Pan S., Li Y., Zhang J. 6-Shogaol Prevents Benzo(a)pyrene-Exposed Lung Carcinogenesis via Modulating PRDX1-Associated Oxidative Stress, Inflammation, and Proliferation in Mouse Models. Environ Toxicol. 2024;39;1:75–84. Doi: 10.1002/tox.23946. PMID: 37638803.
60. Wei T., Wang X., Lang K., Song Y., Luo J., Gu Z., Yang D., Song Y. Peroxiredoxin 6 Protects Pulmonary Epithelial Cells from Cigarette-related Ferroptosis in Chronic Obstructive Pulmonary Disease. Inflammation. 2025;48;2:662–75. Doi: 10.1007/s10753-024-02077-4. PMID: 38954261.
PDF (RUS) Full-text article (in Russian)
Conflict of interest.The authors declare no conflict of interest.
Financing. The work was carried out with the financial support of the Russian Science Foundation, project No. 24-24-00070.
Contribution. Article was prepared with equal participation of the authors.
Article received: 20.03.2026. Accepted for publication: 25.04.2026.